Ionis Pharmaceuticals, Inc. Equity Securities, FV-NI, Cost
Ionis Pharmaceuticals, Inc. (IONS) had Equity Securities, FV-NI, Cost of $21.90 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:EquitySecuritiesFvNiCost · last filed 2026-07-29
- 2026-06-30: Equity Securities, FV-NI, Cost $21.90M.
- 2026-03-31: Equity Securities, FV-NI, Cost $21.90M.
- 2025-12-31: Equity Securities, FV-NI, Cost $16.80M.
- 2025-09-30: Equity Securities, FV-NI, Cost $16.80M.
| Period end | Equity Securities, FV-NI, Cost |
|---|---|
| 2026-06-30 | $21.90M 10-Q · filed 2026-07-29 |
| 2026-03-31 | $21.90M 10-Q · filed 2026-04-29 |
| 2025-12-31 | $16.80M 10-Q · filed 2026-07-29 |
| 2025-09-30 | $16.80M 10-Q · filed 2025-10-29 |
| 2025-06-30 | $16.80M 10-Q · filed 2025-07-30 |
| 2025-03-31 | $35.01M 10-Q · filed 2025-04-30 |
| 2024-12-31 | $35.01M 10-K · filed 2026-02-26 |
| 2024-09-30 | $35.01M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $35.01M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $35.01M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $35.01M 10-K · filed 2025-02-19 |
| 2023-09-30 | $35.01M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $35.01M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $35.01M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $35.01M 10-K · filed 2024-02-21 |
| 2022-09-30 | $38.21M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $35.01M 10-Q · filed 2022-08-09 |
| 2021-12-31 | $27.51M 10-K · filed 2023-02-22 |
| 2019-09-30 | $1.21M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $1.21M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $1.21M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $1.21M 10-Q · filed 2019-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |